Tibra Equities Europe’s Coherus Oncology CHRS Stock Holding History

Tibra Equities Europe’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-13,500	Closed	-$217K	–	19
2021 Q3	$217K	Buy	+13,500	New	+$198K	0.33%	35

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Tibra Equities Europe's CHRS Position: Q4 2021 in Review

Tibra Equities Europe sold out of Coherus Oncology (CHRS) in Q4 2021, closing a stake of 13,500 shares — an estimated $217K sold.

Tibra Equities Europe first reported a position in CHRS in Q3 2021 and held it in 1 quarter. The position peaked at $217K in Q3 2021. 201 funds tracked by Wall St. Rank hold CHRS as of Q4 2021.

Tibra Equities Europe reported no remaining Coherus Oncology position as of Q4 2021 after selling out during the quarter.
Tibra Equities Europe sold 13,500 Coherus Oncology shares in Q4 2021, an estimated $217K.
Tibra Equities Europe first reported a position in Coherus Oncology in Q3 2021 and held it in 1 quarter.
Tibra Equities Europe's Coherus Oncology position peaked at $217K in Q3 2021.
201 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2021.

Based on Tibra Equities Europe's 13F filing for Q4 2021, filed 14 Feb 2022.